Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse

British Journal of Haematology

Volumn 141, Issue 5, 2008, Pages 651-658

  Jin, Ming ^a   Casper, T Charles ^b   Cataland, Spero R ^a   Kennedy, Melanie S ^a   Lin, Shili ^c   Li, Yu J ^d   Wu, Haifeng M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b University of Wisconsin Madison   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

ADAMTS13; Disease surveillance; Logistic regression modelling; Thrombotic thrombocytopenic purpura; Thrombotic thrombocytopenic purpura relapses

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RELAPSE; REMISSION; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ADULT; AGE FACTORS; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 43449135029     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07107.x     Document Type: Article

References (34)

1. Arun, B. Kessler, C.M. (2001) Clinical manifestations and therapy of the hemophilias. In : Hemostasis and Thrombosis (ed. by R.W. Colman, J. Hirsh, V.J. Marder, A.W. Clowes J.N. George pp. 815 824. Lippincott Williams & Wilkins, Philidephia.
2. Bates, D. DebRoy, S. (2004) Linear mixed models and penalized least squares. Journal of Multivariate Analysis, 91, 1 17.
3. van den Berg, H.M. Fischer, K. (2003) Prophylaxis for severe hemophilia: experience from Europe and the United States. Seminars in Thrombosis and Hemostasis, 29, 49 54.
4. Cataland, S.R., Jin, M., Smith, E., Stanek, M. Wu, H.M. (2006a) Full evaluation of an acquired case of thrombotic thrombocytopenic purpura following the surgical resection of glioblastoma multiforme. Journal of Thrombosis and Haemostosis, 4, 2733 2737.
5. Cataland, S.R., Jin, M., Zheng, L., George, J. Wu, H.M. (2006b) An evaluation of cyclosporine alone for the treatment of early recurrences of TTP. Journal of Thrombosis and Hemostasis, 4, 1162 1164.
6. Cataland, S.R., Jin, M., Lin, S., Kennedy, M.S., Kraut, E.H., George, J.N. Wu, H.M. (2007) Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. British Journal Haematology, 139, 486 493.
7. Coppo, P., Wolf, M., Veyradier, A., Bussel, A., Malot, S., Millot, G.A., Daubin, C., Bordessoule, D., Pene, F., Mira, J.P., Heshmati, F., Maury, E., Guidet, B., Boulanger, E., Galicier, L., Parquet, N., Vernant, J.P., Rondeau, E., Azoulay, E. Schlemmer, B. (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. British Journal Haematology, 132, 66 74.
8. Fakhouri, F., Vernant, J.P., Veyradier, A., Wolf, M., Kaplanski, G., Binaut, R., Rieger, M., Scheiflinger, F., Poullin, P., Deroure, B., Delarue, R., Lesavre, P., Vanhille, P., Hermine, O., Remuzzi, G. Grunfeld, J.P. (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood, 106, 1932 1937.
9. Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.L., Vanhille, P., Vernant, J.P., Meyer, D. Veyradier, A. (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood, 109, 2815 2822.
10. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine, 339, 1578 1584.
11. George, J.N. (2006) Clinical practice. Thrombotic thrombocytopenic purpura. New England Journal of Medicine, 354, 1927 1935.
12. Groot, E., Hulstein, J.J., Rison, C.N., de Groot, P.G. Fijnheer, R. (2006) FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 4, 698 699.
13. Howard, M.A., Williams, L.A., Terrell, D.R., Duvall, D., Vesely, S.K. George, J.N. (2006) Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 46, 154 156.
14. Jin, M., Cataland, S.R., Bissell, M. Wu, H.M. (2006) A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. Journal of Thrombosis and Haemostasis, 4, 333 338.
15. Kessler, C.M. (1991) An introduction to factor VIII inhibitors: the detection and quantitation. American Journal of Medicine, 91, 1S 5S.
16. Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A. Miyata, T. (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. British Journal Haematology, 129, 93 100.
17. Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, Jr., J.D., Ginsburg, D. Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura [comment]. Nature, 413, 488 494.
18. Miyata, T., Kokame, K. Banno, F. (2005) Measurement of ADAMTS13 activity and inhibitors. Current Opinion in Hematology, 12, 384 389.
19. Moake, J.L. (2002) Thrombotic microangiopathies. New England Journal of Medicine, 347, 589 600.
20. Motto, D.G., Chauhan, A.K., Zhu, G., Homeister, J., Lamb, C.B., Desch, K.C., Zhang, W., Tsai, H.M., Wagner, D.D. Ginsburg, D. (2005) Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. Journal of Clinical Investigation, 115, 2752 2761.
21. Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M.T. Mannucci, P.M. (2004) von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal Haematology, 127, 433 439.
22. Pinheiro, J. Bates, D. (2000) Mixed Effects Models in S and S-PLUS. Springer, New York.
23. R Development Core Team (2006) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
24. Rieger, M., Mannucci, P.M., Kremer Hovinga, J.A., Herzog, A., Gerstenbauer, G., Konetschny, C., Zimmermann, K., Scharrer, I., Peyvandi, F., Galbusera, M., Remuzzi, G., Bohm, M., Plaimauer, B., Lammle, B. Scheiflinger, F. (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 106, 1262 1267.
25. Rock, G.A., Shumak, K.H., Buskard, N.A., Blanchette, V.S., Kelton, J.G., Nair, R.C. Spasoff, R.A. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New England Journal of Medicine, 325, 393 397.
26. Sadler, J.E. (2006) Thrombotic thrombocytopenic purpura: a moving target. Hematology. American Society of Hematology. Education Program, 415 420.
27. Schall, R. (1991) Estimation in generalized linear models with random effects. Biometrika, 78, 719 727.
28. Scheiflinger, F., Knobl, P., Trattner, B., Plaimauer, B., Mohr, G., Dockal, M., Dorner, F. Rieger, M. (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood, 102, 3241 3243.
29. Tsai, H.M. Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585 1594.
30. Vesely, S.K., George, J.N., Lammle, B., Studt, J.D., Alberio, L., El-Harake, M.A. Raskob, G.E. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 102, 60 68.
31. Whitelock, J.L., Nolasco, L., Bernardo, A., Moake, J., Dong, J.F. Cruz, M.A. (2004) ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. Journal of Thrombosis and Haemostasis, 2, 485 491.
32. Willis, M.S. Bandarenko, N. (2005) Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Seminars in Thrombosis and Hemostasis, 31, 700 708.
33. Zheng, X.L., Kaufman, R.M., Goodnough, L.T. Sadler, J.E. (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood, 103, 4043 4049. Epub 2004 Feb 4024.
34. Zhou, W. Tsai, H.M. (2004) An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thrombosis and Haemostasis, 91, 806 811.